Endo Launches Fortesta, Raises 2011 Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Three years after a new management team stepped in at Endo Pharmaceuticals, the specialtypharma appears to be using M&A to diversify successfully beyond its core pain franchise.
You may also be interested in...
After Spate of Transformative Acquisitions, Endo Reports Robust Growth for 1H 2011
Endo's blended business model appears to be paying off in the near term as the company raises guidance for 2011, driven by the acquisition of American Medical Systems in June and strength in its core franchises.
After Spate of Transformative Acquisitions, Endo Reports Robust Growth for 1H 2011
Endo's blended business model appears to be paying off in the near term as the company raises guidance for 2011, driven by the acquisition of American Medical Systems in June and strength in its core franchises.
Endo's Fortesta To Join Crowded Testosterone Treatment Market In Q1
FDA approved the testosterone gel despite concerns about secondary exposure, but Fortesta will be competing against entrenched rivals and a new treatment from Eli Lilly.